Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy

Biochemical Pharmacology

Volumn 78, Issue 11, 2009, Pages 1366-1373

  Theile, Dirk ^a   Grebhardt, Sina ^a   Haefeli, Walter Emil ^a   Weiss, Johanna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Colorectal cancer; Drug transporters; FOLFOX; Glutathione; Oxalate; Synergism

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC CATION TRANSPORTER 2; OXALIC ACID; OXALIPLATIN; WILSON DISEASE PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CATION TRANSPORT PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; GLUTATHIONE; HUMANS; LEUCOVORIN; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; RNA, MESSENGER;

EID: 70349759344     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.07.006     Document Type: Article

References (35)

1. Andre T., Boni C., Mounedji-Boudiaf, Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
2. Candeil L., Gourdier I., Peyron D., Vezzio N., Copois V., Bibeau F., et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 109 (2004) 848-854
3. Calcagno A.M., Ludwig J.A., Fostel J.M., Gottesman M.M., and Ambudkar S.V. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 3 (2006) 87-93
4. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
5. Huang L., Wang C., Zheng W., Liu R., Yang J., and Tang C. Effects of celecoxib on the reversal of multidrug resistance in human gastric carcinoma by downregulation of the expression and activity of P-glycoprotein. Anticancer Drugs 18 (2007) 1075-1080
6. Hooijberg J.H., de Vries N.A., Kaspers G.J., Pieters R., Jansen G., and Peters G.J. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 58 (2006) 1-12
7. Pratt S., Shepard R.L., Kandasamy R.A., Johnston P.A., Perry W., and Dantzig A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4 (2005) 855-863
8. Oguri T., Bessho Y., Achiwa H., Ozasa H., Maeno K., Maeda H., et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Canc Ther 6 (2007) 122-127
9. Song I.S., Savaraj N., Siddik Z.H., Liu P., Wie Y., Wu C.J., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3 (2004) 1543-1549
10. Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10 (2004) 4661-4669
11. Zhang S., Lovejoy K.S., Shima J.E., Lagpacan L.L., Shu Y., Lapuk A., et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66 (2006) 8847-8857
12. Perez R., Hamilton T.C., and Ozols R.F. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma modell systems. Pharmacol Ther 48 (1990) 19-27
13. El-akawi Z., Abu-hadid M., Perez R., Glavy J., Zdanowicz J., Creaven P.J., et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105 (1996) 5-14
14. Ballatori N., Hammond C.L., Cunningham J.B., Krance S.M., and Marchan R. Molecular mechanism of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol 204 (2005) 238-255
15. Rashed T., Menon M., and Thamilselvan S. Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am J Nephrol 24 (2004) 557-568
16. Scheid C., Koul H., Hill W.A., Luber-Narod J., Kennington L., Honeyman T., et al. Oxalate toxicitiy in LLC-PK1 cells: role of free radicals. Kidney Int 49 (1996) 413-419
17. 2] ligand donor sets: effects of carboxylate leaving groups and steric hindrance on chemical and biological properties. Inorg Chem 45 (2006) 5733-5735
18. Weiss J., Herzog M., König S., Storch C.H., Ketabi-Kiyanvash N., and Haefeli W.E. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 109 (2009) 242-250
19. Storch C.H., Theile D., Lindenmaier H., Haefeli W.E., and Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73 (2007) 1573-1581
20. Peters T., Lindenmaier H., Haefeli W.E., and Weiss J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 291-299
21. Albermann N., Schmitz-Winnenthal F.H., Z'graggen K., Volk C., Hoffmann M.M., Haefeli W.E., et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 70 (2005) 949-958
22. Weiss J., Weis N., Ketabi-Kiyanvash N., Storch C.H., and Haefeli W.E. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 579 (2008) 104-109
23. Weiss J., Dormann S-MG, Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., and Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 (2003) 197-204
24. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59 (2007) 238-245
25. Weiss J., Theile D., Ketabi-Kiyanvash N., Lindenmaier H., and Haefeli W.E. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35 (2007) 340-344
26. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
27. De Graaf D., Sharma R.C., Mechetner E.B., Schimke R.T., and Roninson I.B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93 (1996) 1238-1242
28. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Onc Hematol 53 (2005) 13-23
29. Yuan J.H., Cheng J.Q., Jiang L.Y., Ji W.D., Guo L.F., Liu J.J., et al. Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci 21 (2008) 290-295
30. Ceckova M., Vackova Z., Radilova H., Libra A., Buncek M., and Staud F. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro 22 (2008) 1846-1852
31. Jerremalm E., Videhult P., Alvelius G., Griffiths W.J., Bergman T., Eksborg S., et al. Alkaline hydrolysis of oxaliplatin-isolation and identification of the oxalato monodentate intermediate. J Pharm Sci 91 (2002) 2116-2121
32. Langer R., Specht K., Becker K., Ewald P., Bekesch M., Sarbia M., et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 11 (2005) 7462-7469
33. Ludwig J.A., Szakacs G., Martin S.E., Chu B.F., Cardarelli C., Sauna Z.E., et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 66 (2006) 4808-4815
34. Bergman A.M., Pinedo H.M., Talianidis I., Veerman G., Loves W.J., van der Wilt C.L., et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein overexpressing human cancer cell lines. Br J Cancer 88 (2003) 1963-1970
35. Warr J.R., Bamford A., and Quinn D.M. The preferential induction of apoptosis in multidrug-resistant KB cells by 5-fluorouracil. Cancer Lett 175 (2002) 39-44